Obesity Therapy

No apparent APD356 effect seen on heart in phase IIa trial

Published in Biotech Business Week, September 19th, 2005

Arena Pharmaceuticals, Inc., (ARNA) announced that an assessment of follow-up echocardiograms taken approximately 90 days after patients received their first doses of APD356 in its phase IIa clinical trial indicates no apparent drug effect on heart valves or pulmonary artery pressure after 4 weeks of dosing.

APD356 is Arena's orally administered, internally discovered drug candidate for the treatment of obesity. On May 11, 2005, Arena announced that its phase IIa clinical trial demonstrated a highly statistically significant (p=0.0002) mean weight loss of 2.9 pounds in patients taking the 15 mg dose of APD356 versus 0.7 pounds for the placebo group over the 4 week...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry